Table 2 Univariate and multivariate analyses of LBX2-AS1 expression and patients' survival in the study cohort

Overall survival

 Gender

Male/female

1.236

0.335

2.397

0.808

–

–

–

NA

 Age (years)

≥ 60/< 60

0.961

0.763

1.861

0.477

–

–

–

NA

 Tumor location

Colon/rectum

1.412

0.297

2.223

0.125

–

–

–

NA

 Tumor size (cm)

≥ 5/< 5

1.692

1.396

2.235

0.039

1.247

0.797

1.571

NS

 Differentiation grade

Poor/well + moderate

1.593

1.456

4.153

0.013

1.981

1.446

3.332

0.034

 Local invasion

pT3–4/pT1–2

1.588

2.122

4.672

0.009

1.531

1.361

1.861

0.038

 Lymph node metastasis

N2/N0 + N1

1.954

1.368

2.661

0.034

1.654

1.182

2.151

0.036

 TNM stage

III/I + II

2.181

1.632

3.326

0.018

1.992

1.538

3.034

0.016

 CA19-9 (KU/L)

≥ 37/< 37

1.041

0.406

1.668

0.152

–

–

–

NA

 CEA (ng/mL)

≥ 5/< 5

1.368

0.955

2.174

0.075

–

–

–

NA

 LBX2-AS1 level

High/low

3.157

1.823

5.544

0.011

1.675

1.211

2.841

0.022

Disease-free survival

 Gender

Male/female

1.334

0.577

1.941

0.373

–

–

–

NA

 Age (years)

≥ 60/< 60

1.231

0.361

1.834

0.286

–

–

–

NA

 Tumor location

Colon/rectum

1.279

0.618

1.884

0.823

–

–

–

NA

 Tumor size (cm)

≥ 5/< 5

1.515

1.481

3.346

0.031

0.913

0.745

2.003

NS

 Differentiation grade

Poor/well + moderate

1.912

1.717

3.038

0.021

1.957

1.307

3.057

0.045

 Local invasion

pT3–4/pT1–2

1.564

1.254

2.885

0.015

1.114

0.977

1.932

NS

 Lymph node metastasis

N2/N0 + N1

1.805

1.402

3.366

0.038

1.992

1.334

2.382

0.039

 TNM stage

III/I + II

2.155

1.623

3.135

0.028

1.161

0.887

2.112

NS

 CA19-9 (KU/L)

≥ 37/< 37

1.291

0.752

2.684

0.653

–

–

–

NA

 CEA (ng/mL)

≥ 5/< 5

1.317

0.802

2.793

0.438

–

–

–

NA

 LBX2–AS1 level

High/low

0.738

0.302

1.543

0.328

–

–

–

NA